News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer
Breast Cancer
Jan 12, 2025, 08:51

Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer

Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X:

“Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC.”

Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial | Journal of Clinical Oncology

Authors: Toshinari Yamashita, Shigehira Saji, Toshimi Takano, Yoichi Naito, Michiko Tsuneizumi, Akiyo Yoshimura, Masato Takahashi, Junji Tsurutani, Tsuguo Iwatani, Masahiro Kitada, Hiroshi Tada,  Natsuko Mori, Toru Higuchi, Tsutomu Iwasa, Kazuhiro Araki, Kei Koizumi,  Hiroki Hasegawa, Yohei Uchida, Satoshi Morita, Norikazu Masuda.

Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer

Akiyo Yoshimura cancer Elisabetta Bonzano Hiroki Hasegawa Hiroshi Tada Junji Tsurutani Kazuhiro Araki Kei Koizumi Masahiro Kitada Masato Takahashi Michiko Tsuneizumi Natsuko Mori Norikazu Masuda OncoDaily Oncology Satoshi Morita Shigehira Saji Toru Higuchi Toshimi Takano Toshinari Yamashita Tsuguo Iwatani Tsutomu Iwasa Yohei Uchida Yoichi Naito
Special Coverage
Blog
Apr 15, 2025, 19:08
Parminder Singh: Hitting our fundraising goal for this year at the Hope Foundation for Cancer Research
Positive
Apr 15, 2025, 18:57
The launch of the SIOP Global Mapping Project in Oceania - Young SIOP
Science
Apr 15, 2025, 18:41
Clara Park: ASCO guideline on sentinel lymph node biopsy in early-stage breast cancer
Blog
Apr 15, 2025, 18:40
Join the 27th ESGO 2026 in Copenhagen - European Society of Gynaecological Oncology
Blog
Apr 15, 2025, 18:26
Katie Coleman: What is the cause of kidney cancer?
Blog
Apr 15, 2025, 18:25
Cristina Carrera Álvarez: Back from the motivating 11th WCM2025 and 21st Annual Meeting of the EADO
Blog
Apr 15, 2025, 18:11
Rachna Shroff: Honored to Speak at the Brazilian Group of Gastrointestinal Tumors Meeting
Science
Apr 15, 2025, 18:09
Nieves Martinez Lago: Spanish consensus on the diagnosis and management of ACC
Blog
Apr 15, 2025, 17:59
New guidance for managing gastrointestinal symptoms from cancer treatment - Digestive Cancers Europe
Blog
Apr 15, 2025, 17:49
Michael Hofman: Registrar fellowships positions at Peter MacCallum Cancer Centre
Blog
Apr 15, 2025, 17:48
Sylvester Comprehensive Cancer Center’s 4th Biennial Miami Leukemia Symposium launches next weekend
Blog
Apr 15, 2025, 17:41
Dana is an ALK Positive volunteer who diagnosed in 2020